Latest Breaking News On - Prnewswire mineralys therapeutics inc - Page 1 : comparemela.com

Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant.

United statesDavid rodmanJon congletonCatalys pacificMelyssa weiblePrnewswire mineralys therapeutics incUniversity of maryland school medicineMitsubishi tanabe pharma corporationElixir health public relationsUniversity of maryland medical centerDivision of nephrologyMineralys therapeutics incSuccessfully met primarySecondary endpointsMean placebo adjusted reductionSystolic blood pressure